AU2006274036B2 - Isotopically substituted proton pump inhibitors - Google Patents

Isotopically substituted proton pump inhibitors Download PDF

Info

Publication number
AU2006274036B2
AU2006274036B2 AU2006274036A AU2006274036A AU2006274036B2 AU 2006274036 B2 AU2006274036 B2 AU 2006274036B2 AU 2006274036 A AU2006274036 A AU 2006274036A AU 2006274036 A AU2006274036 A AU 2006274036A AU 2006274036 B2 AU2006274036 B2 AU 2006274036B2
Authority
AU
Australia
Prior art keywords
methoxy
compounds
benzimidazole
trideuteriomethoxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006274036A
Other languages
English (en)
Other versions
AU2006274036A1 (en
AU2006274036A2 (en
Inventor
Michael David
Dieter Haag
Felix Huth
Bernhard Kohl
Bernd Mueller
Wolfgang-Alexander Simon
Oliver Von Richter
Karl Zech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of AU2006274036A1 publication Critical patent/AU2006274036A1/en
Publication of AU2006274036A2 publication Critical patent/AU2006274036A2/en
Application granted granted Critical
Publication of AU2006274036B2 publication Critical patent/AU2006274036B2/en
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: NYCOMED GMBH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
AU2006274036A 2005-07-26 2006-07-26 Isotopically substituted proton pump inhibitors Ceased AU2006274036B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106868.2 2005-07-26
EP05106868 2005-07-26
PCT/EP2006/064666 WO2007012650A1 (en) 2005-07-26 2006-07-26 Isotopically substituted proton pump inhibitors

Publications (3)

Publication Number Publication Date
AU2006274036A1 AU2006274036A1 (en) 2007-02-01
AU2006274036A2 AU2006274036A2 (en) 2008-03-20
AU2006274036B2 true AU2006274036B2 (en) 2012-05-24

Family

ID=35734406

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006274036A Ceased AU2006274036B2 (en) 2005-07-26 2006-07-26 Isotopically substituted proton pump inhibitors

Country Status (17)

Country Link
EP (1) EP1910293A1 (es)
JP (1) JP5448448B2 (es)
KR (1) KR101358509B1 (es)
CN (2) CN101268051B (es)
AR (1) AR054584A1 (es)
AU (1) AU2006274036B2 (es)
BR (1) BRPI0614039A2 (es)
CA (1) CA2615670C (es)
EA (1) EA016814B1 (es)
HK (2) HK1125098A1 (es)
IL (1) IL188773A (es)
MX (1) MX2008000901A (es)
NO (1) NO20080839L (es)
NZ (1) NZ565078A (es)
TW (1) TWI394750B (es)
WO (1) WO2007012650A1 (es)
ZA (1) ZA200800303B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
WO2008127640A2 (en) * 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
US20080255200A1 (en) * 2007-04-11 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
CA2789298A1 (en) 2010-02-12 2011-08-18 Esteve Quimica, S.A. Preparation process of the sodium salt of esomeprazole
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005129A1 (en) * 1978-04-14 1979-10-31 Aktiebolaget Hässle Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation
EP0254588A1 (en) * 1986-07-25 1988-01-27 Tokyo Tanabe Company Limited Imidazo[4,5-b] pyridine compounds, process for preparing same and pharmaceutical compositions containing same
US6818200B2 (en) * 1994-03-25 2004-11-16 Isotechnika Inc. Method of using deuterated calcium channel blockers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040068613A (ko) * 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005129A1 (en) * 1978-04-14 1979-10-31 Aktiebolaget Hässle Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation
EP0254588A1 (en) * 1986-07-25 1988-01-27 Tokyo Tanabe Company Limited Imidazo[4,5-b] pyridine compounds, process for preparing same and pharmaceutical compositions containing same
US6818200B2 (en) * 1994-03-25 2004-11-16 Isotechnika Inc. Method of using deuterated calcium channel blockers

Also Published As

Publication number Publication date
ZA200800303B (en) 2009-01-28
AR054584A1 (es) 2007-06-27
CA2615670A1 (en) 2007-02-01
TW200714596A (en) 2007-04-16
CN102134232B (zh) 2012-11-21
HK1125098A1 (en) 2009-07-31
JP2009502871A (ja) 2009-01-29
HK1160126A1 (en) 2012-08-10
KR101358509B1 (ko) 2014-02-05
AU2006274036A1 (en) 2007-02-01
MX2008000901A (es) 2008-03-26
EA200800203A1 (ru) 2008-08-29
CN102134232A (zh) 2011-07-27
JP5448448B2 (ja) 2014-03-19
TWI394750B (zh) 2013-05-01
KR20080037676A (ko) 2008-04-30
AU2006274036A2 (en) 2008-03-20
WO2007012650A1 (en) 2007-02-01
BRPI0614039A2 (pt) 2011-03-09
EA016814B1 (ru) 2012-07-30
CN101268051B (zh) 2011-08-31
NO20080839L (no) 2008-02-18
NZ565078A (en) 2010-03-26
CA2615670C (en) 2015-01-20
CN101268051A (zh) 2008-09-17
IL188773A (en) 2014-02-27
IL188773A0 (en) 2008-08-07
EP1910293A1 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
AU2006274037B2 (en) Isotopically substituted pantoprazole
AU2006274036B2 (en) Isotopically substituted proton pump inhibitors
NO841754L (no) Fremgangsmaate ved fremstilling av nye fluoralkoksyforbindelser
AU2003289948A1 (en) Process for preparing optically pure active compounds
US7301030B2 (en) Process for preparing (S)-pantoprazole
US7601737B2 (en) Isotopically substituted proton pump inhibitors
ZA200608395B (en) Dialkoxy-imidazopyridines derivatives
US20070244115A1 (en) Amino-Halogen-Imidazopyridines as Proton Pump Inhibitors
CA2447675A1 (en) Novel pyridylmethylaminopyrimidines

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR FROM MULLER, BERND TO MUELLER, BERND

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 FEB 2008

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ TAKEDA GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired